A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers

• Published in: Carbohydrate Polymers
• Main Author: Rasul R.M.; Tamilarasi Muniandy M.; Zakaria Z.; Shah K.; Chee C.F.; Dabbagh A.; Rahman N.A.; Wong T.W.
• Format: Review
• Language: English
• Published: Elsevier Ltd 2020
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089817995&doi=10.1016%2fj.carbpol.2020.116800&partnerID=40&md5=0029fd5e7e61a936786414f395bd41ec

Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance. © 2020 Elsevier Ltd